Bionik Laboratories Corp Stock Fundamentals
Bionik Laboratories Corp fundamentals help investors to digest information that contributes to Bionik Laboratories' financial success or failures. It also enables traders to predict the movement of Bionik Pink Sheet. The fundamental analysis module provides a way to measure Bionik Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bionik Laboratories pink sheet.
Bionik |
Bionik Laboratories Corp Company Current Valuation Analysis
Bionik Laboratories' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bionik Laboratories Current Valuation | 4.84 M |
Most of Bionik Laboratories' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bionik Laboratories Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bionik Laboratories Corp has a Current Valuation of 4.84 M. This is 99.97% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Bionik Laboratories Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bionik Laboratories's current stock value. Our valuation model uses many indicators to compare Bionik Laboratories value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bionik Laboratories competition to find correlations between indicators driving Bionik Laboratories's intrinsic value. More Info.Bionik Laboratories Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bionik Laboratories' earnings, one of the primary drivers of an investment's value.Bionik Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bionik Laboratories' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bionik Laboratories could also be used in its relative valuation, which is a method of valuing Bionik Laboratories by comparing valuation metrics of similar companies.Bionik Laboratories is currently under evaluation in current valuation category among its peers.
Bionik Fundamentals
| Return On Equity | -7.83 | |||
| Return On Asset | -0.64 | |||
| Operating Margin | (3.30) % | |||
| Current Valuation | 4.84 M | |||
| Shares Outstanding | 6.88 M | |||
| Shares Owned By Insiders | 61.64 % | |||
| Shares Owned By Institutions | 1.18 % | |||
| Price To Earning | (3.60) X | |||
| Price To Book | 8.04 X | |||
| Price To Sales | 3.82 X | |||
| Revenue | 1.27 M | |||
| Gross Profit | 953.26 K | |||
| EBITDA | (9.48 M) | |||
| Net Income | (10.41 M) | |||
| Cash And Equivalents | 1.33 M | |||
| Cash Per Share | 0.19 X | |||
| Total Debt | 503.47 K | |||
| Debt To Equity | 0.32 % | |||
| Current Ratio | 2.32 X | |||
| Book Value Per Share | (0.08) X | |||
| Cash Flow From Operations | (4.15 M) | |||
| Earnings Per Share | (1.78) X | |||
| Number Of Employees | 12 | |||
| Beta | -1.02 | |||
| Market Capitalization | 4.27 M | |||
| Total Asset | 4.68 M | |||
| Retained Earnings | (10.65 M) | |||
| Working Capital | 891 K | |||
| Current Asset | 7.15 M | |||
| Current Liabilities | 6.26 M | |||
| Z Score | -4.6 | |||
| Net Asset | 4.68 M |
About Bionik Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bionik Laboratories Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionik Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionik Laboratories Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts. BIONIK LABORATORIES operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange. It employs 12 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Bionik Pink Sheet
Bionik Laboratories financial ratios help investors to determine whether Bionik Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bionik with respect to the benefits of owning Bionik Laboratories security.